Prognosis and management of diabetic patients with acute coronary syndrome

Hellenic Journal of Cardiology

Volumn 46, Issue 2, 2005, Pages 139-147

  Pissimissis, Evangelos G ^a,b   Garoufalis, Stefanos E ^a  

^a TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^b NONE   (Greece)

Author keywords

Acute coronary syndrome; Angioplasty; Coronary bypass surgery; Diabetes mellitus; Platelet GP IIb IIIa inhibitors; Stents

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN; FIBRINOLYTIC AGENT;

CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTE DISORDER; ANGIOCARDIOGRAPHY; COMORBIDITY; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETIC ANGIOPATHY; FEMALE; HEART INFARCTION; HOSPITALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RADIOGRAPHY; RISK ASSESSMENT; STENT; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MYOCARDIAL INFARCTION; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 21244433475     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Malmberg K, Ryden L: Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988; 9: 256-264.
2. Haffner SM, Lehto S, Pyorala K, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
3. Lebru F, Ducimetiere P, Battaglia S, et al: New diagnostic criteria for diabetes and coronary artery disease: Insights from an angiographic study. J Am Coll Cardiol 2001; 37: 1543-1550.
4. Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-942.
5. Malmberg K, Ryden L, Efendie S, for the DIGAMI Study Group: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: Effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
6. Ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic noninsulin-dependent diabetes mellitus: a randomized prospective six year study. Diabetes Res Clin Pract 1995; 28: 103-117.
7. Diaz R, Paolasso EA, Piegas LS, et al: Metabolic modulation of acute myocardial infraction. Circulation 1998; 21: 2227-2234.
8. Klepzig H, Kobert G, Matter C, et al: Sulfonylureas and ischaemic preconditioning. Eur Heart J 1999; 20: 439-446.
9. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
10. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
11. Grede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
12. Ahmed JM, Mehran R, Dangas G, et al: Predictors of late clinical outcomes in patients with unstable angina undergoing percutaneous coronary intervention. J Am Coll Cardiol 2000; 35: 18A.
13. The BARI Investigators: Influence of diabetes on five year mortality and morbidity in a randomized trial comparing PTCA and CABG in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997; 96: 1761-1769.
14. Detre KM, Lombardero MS, Brooks MM, et al: The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigation Investigators. N Engl J Med 2000; 342: 989-997.
15. Basness GW, Peterson ED, Ohman EM, et al: Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997; 96: 2551-2556.
16. Weintraub WS, Stein B, Kosinski A, et al: Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 1998; 31: 10-19.
17. Kosinski AS, Barnhart HX, Weintraub WS, et al and the EAST Investigators: Five-year outcome after coronary surgery or coronary angioplasty: results from the Emory Angioplasty versus Surgery Trial (EAST). Circulation 1995; 91 Suppl 1: 1-543.
18. The RITA Investigators: Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 1993; 311: 573-580.
19. CABRI Trial Participants: First year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation). Lancet 1995; 316: 1179-1181.
20. King S, Kosinski A, Guyton A, et al: Eight-Year Mortality in the Coronary Angioplasty Versus Surgery Trial (EAST). J Am Coll Cardiol 2000; 35: 1119-1121.
21. The BARI Investigators: Seven years outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by Treatment and Diabetic Status. J Am Coll Cardiol 2000, 35; 5: 1124-1129.
22. Friesinger G, Gravin J: Diabetes and the cardiologists: A call to action. J Am Coll Cardiol 2000; 35: 1130-1133.
23. Van Belle, Abolmaali K, Bauters C, et al: Restenosis, late vessel occlusion angioplasty in diabetic patients. J Am Coll Cardiol 1999; 34: 476-485.
24. Aronson D, Bloomgarden Z, Rayfield EJ: Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27: 528-535.
25. Sobel BE: Potentiation of vasculopathy by insulin. Implications from an NHLBI clinical alert. Circulation 1996; 93: 1613-1615.
26. Bauters C, Lablache JM, McFadden EP, Mammon M, Bertrand ML: Relation of coronary angioplasty findings at coronary angioplasty to angiographic restenosis. Circulation 1995; 92: 2473-2479.
27. Kereiakes DJ, Lincoff M, Miler DP, et al: Abciximab therapy and unplanned coronary stent deployment. Circulation 1998; 97: 857-864.
28. King SB: Coronary artery bypass graft or percutaneous coronary interventions in patients with diabetes: Another nail in the coffin or "Too close to call?" J Am Coll Cardiol 2001; 37: 1016-1018.
29. Serruys PW, Unger F, Sousa JE, et al: Randomized comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-1124.
30. Van den Brand MJ, Rensing BJ, Morel MM, et al: The effect of completeness of revascularization on event free survival at one year in the ARTS trial. J Am Coll Cardiol 2002; 39: 559-564.
31. Van Belle E, Bauters C, Hubert E, et al: Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997; 96: 1454-1460.
32. Lincoft AM: Does stenting prevent diabetic arterial shrinkage after percutaneous coronary revascularization? Circulation 1997; 96: 1374-1477.
33. Marso SP, Tanguay JF, Bhatt DL, et al: Optimizing the percutaneous coronary interventional strategy for diabetics. The EPISTENT Experience. Circulation 1997; 98: 1-79.
34. Rodriquez A, Bernardi V, Navia J, et al: Argentine randomized study: Coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30 day and one-year follow up results. J Am Coll Cardiol 2001; 37: 51-58.
35. The SOS Investigators: Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the stent or surgery trial): a randomized controlled trial. Lancet 2002; 360: 965-970.
36. Piraino R, Damonte A, Kirchmann D, et al: Diabetes is not a risk factor for clinical restenosis after coronary stenting. Eur Heart J 2001; 22 (Abstract Suppl.): p. 495.
37. Sueselbeck T, Latsch A, Siry H, et al: Diabetes mellitus is associated with an increased rate of in-stent restenosis in small vessels. Eur Heart J 2001: 22 (Abstract Suppl.): p. 495.
38. Sousa JM, Carralho AC, Lima VE, Hermann LV: Comparison of clinical presentation, FCG, and coronariography in diabetes and nondiabetic women with unstable angina. Eur Heart J 2001; 22 (Abstract Suppl.): p. 723.
39. Sóselhock et al: Role of vessel size as a predictor for the occurrence of in stent restenosis in patients with diabetes. Am J Cardiol 2001; 88: 243-247.
40. Marso SP, Elles S, Tuzcu M, Topol E: The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. J Am Coll Cardiol 1999; 33: 1269-1277.
41. Krolewski AS, Kosinski EJ, Warram JH, et al: Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59: 750-755.
42. Sedlis S, Morrison D, Sethi G, et al: Percutaneous coronary intervention versus coronary bypass graft surgery. Outcome of diabetics in the AWESOME randomized trial and registry. J Am Coll Cardiol 2001; 37: 2 Suppl A, 1A-648A.
43. Favaloro RG: Critical analysis at coronary artery bypass graft surgery: a 30 year journey. J Am Coll Cardiol 1998; 31 (Suppl. B): 1B-63B.
44. Fajadet J, Perrin M, Ban Hayashi E, et al: 210 day follow-up of the RAVEL study: A randomized double blind study with the sirolimus eluting BX Velocity balloon expandable stent in the treatment of patients with de novo coronary artery lesions. J Am Coll Cardiol 2002; 29: Suppl A.
45. Moses JW: The sirolimus-coated BX-Velocity balloon expandable stent (SIRIUS) trial. TCT Meeting. Washington 2002.
46. Natick MA: Taxus IV Drug Eluting Stent Trial TCT Meeting. Washington, 2003.
47. Coler BS: Blockade of platelet GP IIb/IIIa receptors as an antithrombotic energy. Circulation 1995; 92: 2373-2380.
48. The CAPTURE Investigators: Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-1435.
49. The PURSUIT Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibitide in patients with acute coronary syndrome. N. Engl J Med 1998; 339: 436-443.
50. PRISM-PLUS Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infraction. N Engl J Med 1998; 338: 1488-1497.
51. Abizaid A, Komowski R and Mintz G/S et al: The influence of diabetes mellitus on acute and late outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-589.
52. Elezi S, Kastrati A and Fache J et al: Diabetes mellitus and the clinical and angiographie outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-1873.
53. Iwase E, Tawata M, Aida K, et al: A cross-sectional evaluation of spontaneous platelet aggregation in relation to complication in patients with type II diabetes mellitus. Metabolism 1998; 47: 699-705.
54. Knobler H, Savion N, Shekman B, Kotev-Emeth S, Varon D: Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res 1998; 90: 181-190.
55. Tschoepe D, Rossen P: Heart disease in diabetes mellitus: a challenge for early diagnosis and intervention. Exp Clin Endocrinol Diabetes 1998; 106: 16-24.
56. Park SH, Maro SP, Foundl F, et al: Diabetes and the response to arterial injury (abstr). Circulation 1998; 98: 1-8.
57. Akanse T, Yahbee R, Hozumi T, et al: Retinopathy identifies marked influence of coronary flow reserve in patients with diabetes mellitus. J Am Coll Cardiol 1997; 30: 935-941.
58. Yokayama I, Momomura SI, Ohtake T, et al: Reduced myocardial flow reserve in non insulin dependent diabetes mellitus. J Am Coll Cardiol 1997; 30: 1472-1477.
59. Lincoff AM, Cahtt RM, Moliterno DJ, et al: Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 314: 319-327.
60. EPISTENT Investigators Marso SP, Lincoff AM, Ellis SG, et al: Optimizing the percutaneous Interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT diabetic study. Circulation 1999; 100: 2427-2484.
61. Bhatt D, Marso S, Lincoff M, et al: Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 200; 35: 922-928.
62. The EPIC investigation: Use of a monoclonal antibody directed against the platelet IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
63. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1896.
64. The EPISTENT Investigators (Evaluation of Platelet IIb/IIIa Inhibition for Stenting): Randomized placebo-controlled and balloon-angioplasty controlled trial to access safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352: 87-92.
65. Goldberg S, Savage MP, Fischman DL: The interventional cardiologist and the diabetic patients. Have we pushed the envelope too far or not far enough? Circulation 1996; 94: 1804-1806.
66. Abizaid A, Costa MA, Centemero M, et al, on behalf of the ARTS Investigators: Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Insights from the Arterial Revascularization Therapy Study (ARTS) Trial. Circulation 2001; 104: 533-538.
67. Kuntz RE: Importance of considering atherosclerosis progression when choosing a coronary revascularization artery: the diabetes percutaneous transluminal coronary angioplasty dilemma. Circulation 1999; 99: 847-851.
68. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-1505.
69. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the reduction of acute coronary syndrome events in a global organization network: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable angina. Circulation. 1998; 97: 2386-2395.
70. Moliterno DJ: Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B Study. The PARAGON B International Steering Committee. Am Heart J 2000; 139: 563-566.
71. Simoons ML: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial. Lancet 2001; 357: 1915-1924.
72. Roffi M, Chew D, Mukherjee D. et al: Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST segment-elevation acute coronary syndromes. Circulation 2001; 104: 2707-2771.
73. Theroux P, Alexander J Jr, Pharand C, et al: Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infraction: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation. 2000; 102: 2466-2472.
74. The ESPRIT Investigators: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo controlled trial. Lancet 2000; 356: 2037-2044.
75. Stein B, Weintraub WS, Gebhart SP, et al: Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995; 91: 979-989.
76. Kleiman NS, Lincoff AM, Kereiakes DJ, et al: Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial Circulation 1998; 97: 1912-1920.
77. Roff M, Moliterno DT, Meier B, et al: Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: do Tirofiban And ReoPro Give similar Efficacy outcomes Trial (TARGET) 1-year follow-up. Circulation 2002; 105: 2730-2736.